Cancer Immunotherapy Market & Clinical Pipeline Insight

With more than 6 million deaths worldwide in 2013, cancer has become one of the most pressing health problems faced by almost all the economies of the world. Inspite of the fact that there have been significant improvisation and advancements in surgery, radiation therapy, and chemotherapy over the years, there has hardly been any significant control of this disease by these treatments. There have been many developments in the recent past, in terms of introducing novel methods of treatment of cancer, which are likely to have a great potential. Cancer immunotherapy is one such development in the field of cancer treatment. This treatment option involves manipulating the human body's immune system in order to target the cancer.

The recent years have witnessed the emergence of cancer immunotherapy, which has the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past 15-20 years, the researchers have increased their learning about the human body's immune system, which has led to the achievement of significant number of regulatory milestones during this period. Cancer immunotherapy has been made commercial and the market availability of the agents has enabled the pharmaceutical companies to develop novel combination approaches which have the capability to provide even greater insight into the body's immune system.

There has been some extensive research in the previous decade which has led to the development of vital novel therapies for diseases such as bladder cancer, renal cell carcinoma, colon cancer, and some leukemias. Additionally, these significant achievements in cancer immunotherapy have been popular on similar lines as improved techniques such as genetic engineering and monoclonal antibody generation. Thus, both these set of advancements have been working hand-in-hand to bring the cancer immunotherapy on the growth trajectory. The future is also likely to witness a continued close association between these two fields of advancements.

Cancer immunotherapy will continue to be overflowing with huge potential as a result of an increasing number of new discoveries and techniques. Inspite of advances being made in terms of understanding of the complexities of the human immune system, as compared to the

state of immunology during Dr. Coley, there is still significant work which needs to be done. The complete detailed understanding is yet to be deciphered, which is one of the major reasons for cancer immunotherapy not being in widespread use.

"Cancer Immunotherapy Market & Clinical Pipeline Insight" Report Highlights:

- Cancer Immunotherapy Market Overview
- Cancer Immunotherapy Market Dynamics
- Cancer Immunotherapy Pipeline: 1080 Drug in Clinical Pipeline
- Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country
- Cancer Vaccine Clinical Pipeline by Phase & Country
- Oncolytic Viruses Clinical Pipeline by Phase & Country
- Cancer Cytokine Therapy Clinical Trial Insight by Phase & Country
- Cancer Cell Therapy Clinical Trial Insight by Phase & Country
- Currently there are 605 Cancer Monoclonal Antibodies, 289 Cancer Vaccines, 40 Oncolytic Viruses Drugs, 64 Cytokines Therapies & 82 Cell Therapies are in Clinical Pipeline

For Report Sample Contact: avinash@kuickresearch.com

Table of Contents

List of Figures

List of Tables

Following Information For Each Drug Profile in Covered in More than 500 Tables in Report:

- Drug Profile Overview
- Active Indication
- Orphan Designation
- Brand Name
- Phase of Development

- Country for Clinical Trial
- Owner / Originator/ Licensee/Collaborator
- Administrative Route
- Drug Class